Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

1.

Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial.

Belotto-Silva C, Diniz JB, Malavazzi DM, Valério C, Fossaluza V, Borcato S, Seixas AA, Morelli D, Miguel EC, Shavitt RG.

J Anxiety Disord. 2012 Jan;26(1):25-31. doi: 10.1016/j.janxdis.2011.08.008. Epub 2011 Aug 19.

PMID:
21907540
[PubMed - indexed for MEDLINE]
2.

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

Simpson HB, Gorfinkle KS, Liebowitz MR.

J Clin Psychiatry. 1999 Sep;60(9):584-90.

PMID:
10520976
[PubMed - indexed for MEDLINE]
3.

The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.

Shavitt RG, Valério C, Fossaluza V, da Silva EM, Cordeiro Q, Diniz JB, Belotto-Silva C, Cordioli AV, Mari J, Miguel EC.

Eur Arch Psychiatry Clin Neurosci. 2010 Mar;260(2):91-9. doi: 10.1007/s00406-009-0015-3.

PMID:
20077119
[PubMed - indexed for MEDLINE]
4.

Clinical predictors of long-term outcome in obsessive-compulsive disorder.

Jakubovski E, Diniz JB, Valerio C, Fossaluza V, Belotto-Silva C, Gorenstein C, Miguel E, Shavitt RG.

Depress Anxiety. 2013 Aug;30(8):763-72. doi: 10.1002/da.22013. Epub 2012 Oct 25.

PMID:
23109056
[PubMed - indexed for MEDLINE]
5.

Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.

Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J.

J Clin Psychiatry. 2001 Jul;62(7):535-40.

PMID:
11488364
[PubMed - indexed for MEDLINE]
6.

Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.

Bergeron R, Ravindran AV, Chaput Y, Goldner E, Swinson R, van Ameringen MA, Austin C, Hadrava V.

J Clin Psychopharmacol. 2002 Apr;22(2):148-54.

PMID:
11910259
[PubMed - indexed for MEDLINE]
7.

Predictors of response to group cognitive-behavioral therapy in the treatment of obsessive-compulsive disorder.

Raffin AL, Guimarães Fachel JM, Ferrão YA, Pasquoto de Souza F, Cordioli AV.

Eur Psychiatry. 2009 Jun;24(5):297-306. doi: 10.1016/j.eurpsy.2008.12.001. Epub 2009 Feb 5.

PMID:
19200694
[PubMed - indexed for MEDLINE]
8.

A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.

Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC.

J Clin Psychopharmacol. 2011 Dec;31(6):763-8. doi: 10.1097/JCP.0b013e3182367aee.

PMID:
22020357
[PubMed - indexed for MEDLINE]
9.

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.

J Clin Psychiatry. 2004 Apr;65(4):565-8.

PMID:
15119922
[PubMed - indexed for MEDLINE]
10.

Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study.

Anand N, Sudhir PM, Math SB, Thennarasu K, Janardhan Reddy YC.

J Anxiety Disord. 2011 Oct;25(7):939-45. doi: 10.1016/j.janxdis.2011.05.007. Epub 2011 Jun 1.

PMID:
21689902
[PubMed - indexed for MEDLINE]
11.

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Ringold AL, Elliott MA.

J Clin Psychiatry. 2000 Jul;61(7):514-7.

PMID:
10937610
[PubMed - indexed for MEDLINE]
12.

Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.

Kampman M, Keijsers GP, Hoogduin CA, Verbraak MJ.

Acta Psychiatr Scand. 2002 Oct;106(4):314-9.

PMID:
12225499
[PubMed - indexed for MEDLINE]
13.

Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.

Besiroglu L, Çetinkaya N, Selvi Y, Atli A.

Compr Psychiatry. 2011 Sep-Oct;52(5):556-61. doi: 10.1016/j.comppsych.2010.10.003. Epub 2010 Dec 15.

PMID:
21109243
[PubMed - indexed for MEDLINE]
14.

A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder.

Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV.

J Clin Psychiatry. 2006 Jul;67(7):1133-9.

PMID:
16889458
[PubMed - indexed for MEDLINE]
15.

Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder.

Asbahr FR, Castillo AR, Ito LM, Latorre MR, Moreira MN, Lotufo-Neto F.

J Am Acad Child Adolesc Psychiatry. 2005 Nov;44(11):1128-36.

PMID:
16239861
[PubMed - indexed for MEDLINE]
16.

Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.

Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L.

Am J Psychiatry. 1999 Sep;156(9):1409-16.

PMID:
10484953
[PubMed - indexed for MEDLINE]
17.

Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Aboujaoude E, Gamel NN.

J Clin Psychiatry. 2009 Nov;70(11):1530-5. doi: 10.4088/JCP.08m04605. Epub 2009 Jun 30.

PMID:
19573497
[PubMed - indexed for MEDLINE]
18.

A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder.

Saxena S, Winograd A, Dunkin JJ, Maidment K, Rosen R, Vapnik T, Tarlow G, Bystritsky A.

J Clin Psychiatry. 2001 Jan;62(1):67-72; quiz 73.

PMID:
11235937
[PubMed - indexed for MEDLINE]
19.

Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.

Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R.

J Clin Psychiatry. 2007 Oct;68(10):1552-6.

PMID:
17960971
[PubMed - indexed for MEDLINE]
20.

Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder.

Hoexter MQ, Dougherty DD, Shavitt RG, D'Alcante CC, Duran FL, Lopes AC, Diniz JB, Batistuzzo MC, Evans KC, Bressan RA, Busatto GF, Miguel EC.

Eur Neuropsychopharmacol. 2013 Jul;23(7):569-80. doi: 10.1016/j.euroneuro.2012.06.014. Epub 2012 Jul 27.

PMID:
22841131
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk